Expert Analysis
Latest Findings in HBV Management
Source: CCO Independent Conference Coverage of the 2005 Annual Meeting of the American Association for the Study of Liver Diseases*
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
Latest Findings in HBV Management
  
- Geoffrey M. Dusheiko, MD, FCP(SA), FRCP
- Robert G. Gish, MD
- Emmet B. Keeffe, MD, MACP
|
 |
|
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the prevalence of HBV in specific subpopulations.
- Review approaches for minimizing/avoiding the development of drug resistance during treatment of chronic hepatis B including rationale for the development of antiviral combinations.
- Describe the results of recent studies of antiviral agents for the treatment of chronic hepatitis B, including adefovir dipivoxil, clevudine, entecavir, peginterferon, pradefovir, telbivudine, and tenofovir.
Topics covered include:
- Prevalence of Hepatitis B
- Fibrosis in Patients With Immunotolerance to Chronic HBV
- AASLD Survey: Current Approaches to Treatment of CHB
- Clinical Trials of Telbivudine, and Early Predictors of Outcomes
- Entecavir Resistance in Treatment-Naive and Lamivudine-Refractory Patients
- Treatment of Lamivudine-Resistant Disease With Adefovir, Tenofovir, and Combination Therapy
- Clevudine in HBeAg-Positive Patients
- Pradefovir Mesylate vs Adefovir Dipivoxil
- Conclusion
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
CCO Resources
CCO Expert Recap of data from the 2005 Annual Meeting of the American Association for the Study of Liver Diseases
|
|